A Phase Ib Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALG-801 in Postmenopausal Women
Latest Information Update: 09 Jan 2025
At a glance
- Drugs BIIB 110 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors AliveGen
Most Recent Events
- 22 Mar 2024 New trial record
- 18 Mar 2024 Results presented in the AliveGen Media Release.